64 results on '"Claudia Rutherford"'
Search Results
2. Single-arm studies involving patient-reported outcome data in oncology: a literature review on current practice
- Author
-
Limin Liu, Jungyeon Choi, Jammbe Z Musoro, Willi Sauerbrei, Cecilie Delphin Amdal, Ahu Alanya, Yolanda Barbachano, Joseph C Cappelleri, Ragnhild Sørum Falk, Mallorie H Fiero, Antoine Regnault, Jaap C Reijneveld, Rickard Sandin, Doranne Thomassen, Satrajit Roychoudhury, Els Goetghebeur, Saskia le Cessie, Olalekan Lee Aiyegbusi, Ethan Basch, Melanie Calvert, Alicyn Campbell, Joseph Cappelleri, Samantha Cruz Rivera, Mallorie Fiero, Rajesh Kamalakar, Karen Keating, Paul Kluetz, Geert Molenberghs, Jammbe Musoro, David Ness, Khadija Rantell, Jaap Reijneveld, Gerhard Rumpold, Alexander Russell-Smith, Claudia Rutherford, Kavita Sail, Maxime Sasseville, Anja Schiel, Michael Schlichting, Kathy Soltys, Ragnhild Sorum Falk, Yun Su, Silene ten Seldam, and Kelly Van Lancker
- Subjects
Oncology - Abstract
Patient-reported outcomes (PROs) are increasingly used in single-arm cancer studies. We reviewed 60 papers published between 2018 and 2021 of single-arm studies of cancer treatment with PRO data for current practice on design, analysis, reporting, and interpretation. We further examined the studies’ handling of potential bias and how they informed decision making. Most studies (58; 97%) analysed PROs without stating a predefined research hypothesis. 13 (22%) of the 60 studies used a PRO as a primary or co-primary endpoint. Definitions of PRO objectives, study population, endpoints, and missing data strategies varied widely. 23 studies (38%) compared the PRO data with external information, most often by using a clinically important difference value; one study used a historical control group. Appropriateness of methods to handle missing data and intercurrent events (including death) were seldom discussed. Most studies (51; 85%) concluded that PRO results supported treatment. Conducting and reporting of PROs in cancer single-arm studies need standards and a critical discussion of statistical methods and possible biases. These findings will guide the Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Data in Cancer Clinical Trials–Innovative Medicines Initiative (SISAQOL-IMI) in developing recommendations for the use of PRO-measures in single-arm studies.
- Published
- 2023
3. The Feasibility, Acceptability, and Effectiveness of Electronic Patient-Reported Outcome Symptom Monitoring for Immune Checkpoint Inhibitor Toxicities: A Systematic Review
- Author
-
Julia Lai-Kwon, Jordan E. Cohen, Karolina Lisy, Claudia Rutherford, Afaf Girgis, Ethan Basch, and Michael Jefford
- Subjects
General Medicine - Abstract
PURPOSE Increasing use of immune checkpoint inhibitors (ICIs) in routine cancer care will increase the incidence of immune-related adverse events (irAEs). Systems are needed to support remote monitoring for irAEs. Electronic patient-reported outcome (ePRO) symptom monitoring systems can help monitor and manage symptoms and side effects. We assessed the content and features of ePRO symptom monitoring systems for irAEs, and their feasibility, acceptability, and impact on patient outcomes and health care utilization. METHODS A systematic literature search was conducted in May 2022 on MEDLINE, Embase, PsycINFO, and Cochrane Central Register of Controlled Trials. Quantitative and qualitative data relevant to the review questions were extracted and synthesized in tables. RESULTS Seven papers describing five ePRO systems were included. All systems collected PROs between clinic visits. Two of five used validated symptom questionnaires, 3/5 provided prompts to complete questionnaires, 4/5 provided reminders to self-report, and 3/5 provided clinician alerts for severe/worsening side effects. Four of five provided coverage of ≥26/30 irAEs in the ASCO irAE guideline. Feasibility and acceptability were demonstrated with consent rates of 54%-100%, 17%-27% of questionnaires generating alerts, and adherence rates of 74%-75%. One paper showed a reduction in grade 3-4 irAEs, treatment discontinuation, clinic visit duration, and emergency department presentations, while another showed no difference in these outcomes or the rate of steroid use. CONCLUSION There is preliminary evidence of the feasibility and acceptability of ePRO symptom monitoring for irAEs. However, further studies are needed to confirm the impact on ICI-specific outcomes, such as the frequency of grade 3-4 irAEs and duration of immunosuppression. Suggestions for the content and features of future ePRO systems for irAEs are provided.
- Published
- 2023
4. Introduction to the special section 'Reducing research waste in (health-related) quality of life research'
- Author
-
Claudia Rutherford and Jan R. Böhnke
- Subjects
Public Health, Environmental and Occupational Health - Abstract
Research waste relating to the production and reporting of health and medical research is a major problem. Each year, resources are wasted on research that asks the wrong questions, uses inappropriate designs, includes unrepresentative or small samples, uses incorrect methods of analysis, and is inappropriately reported, disseminated, or translated into decision-making. These issues are pertinent to (health-related) quality of life ((HR)QL)/patient-reported outcome (PRO) research. In an attempt to reduce waste and maximise efficiency, the Lancet’s REWARD (REduce research Waste And Reward Diligence) Campaign invited everyone involved in research to critically examine how they work to reduce waste and maximise efficiency, and to strive to improve the value of the funds invested in the research we commission, deliver, publish, and implement. However, despite nearly a decade since the Lancet series, research waste is still a major problem. In 2021, the Editors of Quality of Life Research journal issued a call for papers on reducing (HR)QL/PRO research waste and optimizing (HR)QL/PRO data. Papers in the special section discuss the many contributors to research waste and the editors, in their editorial, highlight the ongoing issues that as researchers we should all be mindful of, and potential ways in which we could all do our bit to reduce research waste in the (HR)QL/PRO field.
- Published
- 2022
5. Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use
- Author
-
Tiffany Li, Susanna B. Park, Eva Battaglini, Madeleine T. King, Matthew C. Kiernan, David Goldstein, and Claudia Rutherford
- Subjects
Psychometrics ,Surveys and Questionnaires ,Quality of Life ,Public Health, Environmental and Occupational Health ,Humans ,Peripheral Nervous System Diseases ,Antineoplastic Agents ,Female ,Patient Reported Outcome Measures - Abstract
Purpose Chemotherapy-induced peripheral neuropathy (CIPN) is a common toxicity of cancer treatment, with potential to significantly impact cancer survivors’ long-term quality of life. Patient reported outcome measures (PROMs) are increasingly utilised to evaluate CIPN. However, guidance remains lacking on how to identify fit for purpose PROMs with considerations necessarily differing when used in various research and in-clinic contexts. This study aimed to evaluate evidence about CIPN PROMs measurement properties and propose considerations to optimize CIPN PROM selection for each purpose. Methods A systematic review was conducted to identify literature assessing measurement properties of CIPN PROMs. These were evaluated against Consensus-based Standards for the selection of health Measurement Instruments (COSMIN) criteria and International Society for Quality of Life minimum standards. Risk of Bias (RoB) was assessed using the COSMIN RoB checklist. Results Thirty-nine papers evaluating measurement properties of 13 PROMs were included. The European Organization for Research and Treatment of Cancer Quality of Life Chemotherapy-Induced Peripheral Neuropathy Questionnaire (QLQ-CIPN20) and Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) were the most commonly investigated PROMs and had the most measurement properties meeting established criteria. Conclusion The use of the QLQ-CIPN20 and FACT/GOG-Ntx to assess CIPN in research settings has the most supporting evidence. However other considerations including study aims, endpoints and target population also factor into PROM selection and need to be considered more often when determining the most suitable outcome measure. Evidence of CIPN PROMs use in clinical practice is limited and their adoption to individual-patient level management requires more evaluation.
- Published
- 2022
6. How consequences of colorectal cancer treatment are managed: a qualitative study of stakeholder experiences about supportive care and current practices
- Author
-
Claudia Rutherford, Angela Ju, Bora Kim, Lisette Wiltink, Louise Acret, and Kate White
- Subjects
Oncology - Abstract
Purpose Colorectal cancer (CRC) survivors experience treatment-effects such as symptoms and functional impairments. There is limited evidence about how these are managed and what services or supports are available in the community. We aimed to identify current practice and available supports for managing consequences of treatment from clinician and CRC survivor perspectives. Methods This qualitative study, informed by an interpretivist constructionist paradigm, included semi-structured interviews. Clinicians with experience of treating CRC patients and adult CRC survivors were recruited across Australia. Interviews explored experiences about problems experienced after CRC treatment and how these were managed. Data collection and analysis, using thematic analysis, was iterative whereby emergent themes during analysis were incorporated into subsequent interviews. Results We interviewed 16 clinicians and 18 survivors. Survivors experienced a range of consequences of treatment amendable to support including allied health, information, and self-management. Barriers to support access included clinicians’ worry about patient out-of-pocket expenses, long waitlists, lack of awareness about existing supports, and perception no therapeutic options were available. Healthcare professionals with expertise in CRC were often difficult to identify outside of cancer settings. Survivorship care could be improved with individualised timely information and identification of pathways to access healthcare providers with expertise in managing consequences of CRC treatment within primary care. Conclusions To improve CRC survivor lives posttreatment, routine assessment of consequences of treatment, individualised care planning involving relevant healthcare professionals, access to supportive care when needed, and improved information provision and engagement of a range of health professionals in follow-up care are needed.
- Published
- 2023
7. Using feedback tools to enhance the quality and experience of care
- Author
-
Jan R. Boehnke and Claudia Rutherford
- Subjects
medicine.medical_specialty ,Process management ,Public health ,media_common.quotation_subject ,Public Health, Environmental and Occupational Health ,medicine ,Quality (business) ,Psychology ,Quality of Life Research ,media_common - Published
- 2021
8. Introduction to the special section 'Reducing research waste in (health-related) quality of life research'
- Author
-
Claudia, Rutherford and Jan R, Boehnke
- Subjects
Psychotherapy ,Quality of Life ,Humans - Published
- 2022
9. 135 Treating low-risk ductal carcinoma in situ (DCIS)... or not? Qualitative study of patient perspectives
- Author
-
Jolyn Hersch, Brooke Nickel, Ann Dixon, Nehmat Houssami, Christobel Saunders, Jesse Jansen, Claudia Rutherford, Alexandra Barratt, Andrew Spillane, Liz Wylie, Kirsty Stuart, Geraldine Robertson, and Kirsten McCaffery
- Published
- 2022
10. 132 Treating (or Monitoring?) Low-Risk Ductal Carcinoma in Situ (DCIS): Focus Groups about Women’s Views
- Author
-
Jolyn Hersch, Brooke Nickel, Ann Dixon, Jesse Jansen, Christobel Saunders, Nehmat Houssami, Alexandra Barratt, Andrew Spillane, Kirsty Stuart, Claudia Rutherford, Geraldine Robertson, Liz Wylie, and Kirsten McCaffery
- Published
- 2022
11. How is quality of life defined and assessed in published research?
- Author
-
Madeleine King, Daniel S.J. Costa, Rebecca Mercieca-Bebber, Margaret-Ann Tait, and Claudia Rutherford
- Subjects
medicine.medical_specialty ,Public health ,Meaningful use ,Public Health, Environmental and Occupational Health ,humanities ,Terminology ,law.invention ,Consistency (negotiation) ,Quality of life ,law ,medicine ,CLARITY ,Construct (philosophy) ,Psychology ,Quality of Life Research ,Clinical psychology - Abstract
To ensure clarity in communication in the field of quality of life research, and meaningful use of ‘quality of life’ as a research outcome, requires two things: awareness that there is a range of conceptualisations and definitions of ‘quality of life’, and for any particular study, consistency between the way the term is defined and operationalised in that setting. We aimed to identify how frequently research articles described (HR)QOL as a construct of interest, how frequently they referred to “patient-reported outcome (measures)”, which patient-reported outcome measures were used, and how (HR)QOL was defined. We reviewed all Quality of Life Research articles published in 2017 and recorded whether they described health-related quality of life or quality of life as constructs of interest, and/or mentioned the term(s) patient-reported outcome (measures). We recorded definitions of (HR)QOL stated and questionnaires used. We classified articles according to constructs assessed and instruments used, and examined whether articles citing the same definition used the same questionnaires. We reviewed 300 articles; 65% stated that (HR)QOL was a construct of interest, 27% mentioned patient-reported outcome (measures), and 20% mentioned neither. Fifty-one articles provided definitions of (HR)QOL, citing 66 sources, with 11 definitions cited more than once. PROMIS, SF, EQ-5D, and EORTC instruments were the most commonly used. The only definition and questionnaire consistently used together were the WHO definitions/instruments. These results demonstrate considerable heterogeneity in the definition and operationalisation of (HR)QOL, between and within studies. This limits meaningful interpretation of (HR)QOL scores and complicates literature searches. Investigators should define constructs and select instruments aligned with their definitions.
- Published
- 2021
12. Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes
- Author
-
Tiffany Li, Hannah C. Timmins, Terry Trinh, David Mizrahi, Michelle Harrison, Lisa G. Horvath, Peter Grimison, Michael Friedlander, Matthew C. Kiernan, Madeleine T. King, Claudia Rutherford, David Goldstein, and Susanna B. Park
- Subjects
Oncology - Abstract
Background: Chemotherapy-induced peripheral neurotoxicity (CIPN) is a common complication of cancer treatment that produces functional disability. Increasingly, patient-reported outcome measures (PROMs) are used to assess CIPN, providing a broader symptom perspective than clinician-graded scales. Understanding when a reported change in CIPN symptoms meets the threshold for clinical significance is challenging. This study aimed to provide interpretation guidelines for validated CIPN PROMs, and thereby enable estimation of thresholds to identify clinically relevant symptoms. Methods: Patients commencing neurotoxic cancer treatments were assessed at 3 timepoints: baseline, midtreatment, and end-of-treatment. Trajectory of CIPN development was assessed by means of CIPN PROMs, EORTC Quality of Life – Chemotherapy-Induced Peripheral Neuropathy questionnaire (QLQ-CIPN20), and Functional Assessment of Cancer Therapy/Gynecologic Oncology Group – Neurotoxicity questionnaire (FACT/GOG-NTX). Thresholds were estimated for CIPN PROMs using the NCI CTCAE sensory neuropathy scale as the clinical anchor by midtreatment and end-of-treatment. Patients were assigned to a clinical change group according to CIPN development: either no development; grade 1 neuropathy (minimally important difference [MID]); or grade 2 neuropathy (clinically important difference). Distribution-based estimates (SD, 0.5) were also evaluated as supportive evidence. Results: In total, 406 patients were recruited to the study, of whom 62% (n=199/320) developed CIPN by midtreatment and 80% (n=274/343) by end-of-treatment. Anchor-based MID estimates by midtreatment were 5.06 (95% CI, 4.26–5.86) for the QLQ-CIPN20 and 3.54 (95% CI, 2.87–4.20) for the FACT/GOG-NTX. End-of-treatment MIDs were estimated to be 7.32 (95% CI, 6.23–8.40) for the QLQ-CIPN20 and 4.84 (95% CI, 3.98–5.70) for the FACT/GOG-NTX. Distribution-based MID estimations yielded lower values than anchor-based methods, at 3.73 for the QLQ-CIPN20 and 2.64 for the FACT/GOG-NTX at midtreatment and 5.52 for the QLQ-CIPN20 and 3.64 for the FACT/GOG-NTX at end-of-treatment. Conclusions: Findings from the present series aid meaningful interpretation for commonly used validated CIPN PROMs and provide thresholds that serve as guidance on how to interpret score changes, which will be useful for design and evaluation of clinical trials and clinical practice.
- Published
- 2023
13. Patient-reported outcomes in non-muscle invasive bladder cancer: a mixed-methods systematic review
- Author
-
Madeleine King, Claudia Rutherford, Daniel S.J. Costa, Margaret-Ann Tait, Manish I. Patel, Shomik Sengupta, and David Smith
- Subjects
medicine.medical_specialty ,Chronic condition ,Bladder cancer ,business.industry ,030503 health policy & services ,Public Health, Environmental and Occupational Health ,MEDLINE ,Context (language use) ,PsycINFO ,medicine.disease ,Treatment and control groups ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,Maintenance therapy ,030220 oncology & carcinogenesis ,medicine ,0305 other medical science ,Intensive care medicine ,business - Abstract
Non-muscle invasive bladder cancer (NMIBC) is a chronic condition requiring repeated treatment and endoscopic examinations that can occur life-long. In this context, patient-reported outcomes (PROs) are important considerations to patients and managing clinicians. We undertook a systematic review to synthesise PRO results relevant to NMIBC treatment to explore trajectories overtime and differences between treatment options. We searched databases AMED, MEDLINE, EMbase, PsycINFO, Web of Knowledge and Scopus (inception to 5th December 2019), reference lists and contacted key authors to identify studies that reported PROs after NMIBC treatment. Two reviewers independently applied inclusion and quality criteria and extracted findings. Results for PROs were synthesised for treatment groups across three time periods: acute/during induction therapy; during maintenance therapy; and long-term follow-up (> 1 year). Of 3193 papers screened, 29 were eligible. These provided evidence about induction treatment effects, but few reported maintenance or long-term evidence, and evidence about differences between NMIBC treatment options was lacking. A range of symptoms (pain in bladder area, urinary frequency and urgency, pain or burning during urination) were commonly experienced during and soon after treatment for NMIBC. Less common symptoms included fatigue, disrupted sleep and gastrointestinal problems. Treatments for NMIBC can cause symptoms and functional impairment during the acute treatment phase and reduce quality of life. Clinicians should be aware of these impairments to prepare patients for short-term sequelae and enable those with treatment options to exercise preferences in choosing among them. However, gaps in current evidence limit our understanding of PRO trajectories from diagnosis through to long-term survivorship and treatment effects.
- Published
- 2020
14. Establishing a Core Outcome Set for Peritoneal Dialysis: Report of the SONG-PD (Standardized Outcomes in Nephrology–Peritoneal Dialysis) Consensus Workshop
- Author
-
Karine E. Manera, David W. Johnson, Jonathan C. Craig, Jenny I. Shen, Talia Gutman, Yeoungjee Cho, Angela Yee-Moon Wang, Edwina A. Brown, Gillian Brunier, Jie Dong, Tony Dunning, Rajnish Mehrotra, Saraladevi Naicker, Roberto Pecoits-Filho, Jeffrey Perl, Martin Wilkie, Allison Tong, Adeera Levin, Adrian Liew, Alfonso Cueto Manzano, Ali Abu Alfa, Alicia Neu, Amanda Baumgart, Amelie Bernier-Jean, Amy Kelly, Ana Figueiredo, Andrea Matus, Andrea Viecelli, Angela Ju, Anjali Saxena, Ankit Sharma, Annie-Claire Nadeau-Fredette, Armando Teixeira-Pinto, Asher Mendelson, Ayano Kelly, Bak Leong Goh, Benedicte Sautenet, Braden Manns, Brenda Hemmelgarn, Bruce Robinson, Camilla Hanson, Catherine Cheung, Chandana Guha, Charlotte Logeman, Cheuk-Chun Szeto, Claudia Rutherford, Daniel Schwartz, Daniel Sumpton, David Johnson, David Wheeler, Edwina Brown, Emma O’Lone, Eric Au, Eric Goffin, Fred Finkelstein, Georgi Abraham, Greg Germino, Helen Hurst, Hideki Kawanishi, Htay Htay, Hui Kim Yap, Isaac Teitelbaum, Jenny Chen, Jenny Shen, Joanna Neumann, Joanne Bargman, Johann Morelle, Jonathan Craig, Kajiru Gad Kilonzo, Karen Yeates, Karine Manera, Karolis Azukaitis, Kim Linh Van, Louese Dunn, Mahesh Krishnan, Mark Lambie, Martin Howell, Martin Schreiber, Matthew Oliver, Mauricio Rafael Sanabria, Melissa Nataatmadja, Monika Lichodziejewska-Niemierko, Nancy Verdin, Neelam Mann, Neil Boudville, Nicole Evangelidis, Nicole Scholes-Robertson, Peter Blake, Peter Nourse, Peter Tugwell, Philip Kam-Tao Li, Richard McGee, Robert Quinn, Sally Crowe, Samaya Anumudu, Sarah Bernays, Sarala Naicker, Scott Wilson, Sharon Nessim, Sharon Teo, Simon A. Carter, Simon Davies, Soheli Ahmed Sweety, Ted Toffelmire, Vanita Jassal, Vivekanand Jha, Viviane Calice da Silva, Wim Van Biesen, Wolfgang Winkelmayer, Yasuhiko Ito, Yong-Lim Kim, Zeeshan Butt, MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Nantes (UN)-Université de Nantes (UN), UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, and Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques
- Subjects
Nephrology ,Delphi Technique ,[SDV]Life Sciences [q-bio] ,medicine.medical_treatment ,030232 urology & nephrology ,Psychological intervention ,Disease ,patient-centered care ,outcomes ,Outcome (game theory) ,Peritoneal dialysis (PD) ,law.invention ,0302 clinical medicine ,Randomized controlled trial ,law ,Outcome Assessment, Health Care ,technique survival ,Medicine ,PD failure ,030212 general & internal medicine ,Empowerment ,caregiver ,media_common ,cardiovascular disease (CVD) ,PD-related infection ,trials ,patient-reported outcome (PRO) ,3. Good health ,Research Design ,life participation ,Peritoneal Dialysis ,consensus workshop ,medicine.medical_specialty ,Consensus ,media_common.quotation_subject ,core outcome set ,Peritoneal dialysis ,03 medical and health sciences ,quality of life (QoL) ,nephrology research ,Internal medicine ,Humans ,Dialysis ,business.industry ,patient perspective ,mortality ,Family medicine ,trial design ,dialysis ,fatigue ,business - Abstract
International audience; Outcomes reported in randomized controlled trials in peritoneal dialysis (PD) are diverse, are measured inconsistently, and may not be important to patients, families, and clinicians. The Standardized Outcomes in Nephrology-Peritoneal Dialysis (SONG-PD) initiative aims to establish a core outcome set for trials in PD based on the shared priorities of all stakeholders. We convened an international SONG-PD stakeholder consensus workshop in May 2018 in Vancouver, Canada. Nineteen patients/caregivers and 51 health professionals attended. Participants discussed core outcome domains and implementation in trials in PD. Four themes relating to the formation of core outcome domains were identified: life participation as a main goal of PD, impact of fatigue, empowerment for preparation and planning, and separation of contributing factors from core factors. Considerations for implementation were identified: standardizing patient-reported outcomes, requiring a validated and feasible measure, simplicity of binary outcomes, responsiveness to interventions, and using positive terminology. All stakeholders supported inclusion of PD-related infection, cardiovascular disease, mortality, technique survival, and life participation as the core outcome domains for PD.
- Published
- 2020
15. Quality of Life in Women with Ovarian Cancer
- Author
-
Rachel Campbell, Madeleine T. King, Yeh Chen Lee, Linda Mileshkin, Margaret-Ann Tait, and Claudia Rutherford
- Published
- 2022
16. A conceptual framework of patient‐reported outcomes in people with venous leg ulcers
- Author
-
Louise Turnour, Carolina D Weller, Rasa Ruseckaite, Claudia Rutherford, Peter Franks, Catelyn Richards, and Victoria Team
- Subjects
Male ,medicine.medical_specialty ,Attitude of Health Personnel ,MEDLINE ,Compression bandaging ,Dermatology ,Prom ,Varicose Ulcer ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Quality of life (healthcare) ,medicine ,Humans ,In patient ,Patient Reported Outcome Measures ,Aged ,Face validity ,Aged, 80 and over ,business.industry ,Qualitative interviews ,Australia ,Middle Aged ,humanities ,Conceptual framework ,Patient Satisfaction ,Family medicine ,Quality of Life ,Female ,Surgery ,Symptom Assessment ,business - Abstract
Venous leg ulcers (VLUs) are a common chronic often undertreated condition, which affects individual's health-related quality of life (HRQoL). Numerous patient-reported outcome measures (PROMs) have been validated to capture HRQoL in patients with VLUs. However, available instruments contain many items, are hard to use in clinical practice, and present with weak responsiveness. This study aims to determine clinical utility of an existing VLU-QoL instrument and to develop a comprehensive PROs assessment framework to guide clinical practice treatment in people with VLUs in Australia. Semi-structured qualitative interviews were conducted with VLU patients (N = 13) and their managing clinicians (N = 6) in Victoria, Australia. Interview topics covered content and face validity, appropriateness, and acceptability of the VLU-QoL instrument to determine suitable and appropriate for use in clinical practice. Clinicians and patients agreed that a VLU-QoL instrument was needed in clinical practice. Both clinicians and patients agreed it would be appropriate to answer PROMs questions prior to consultation with clinicians every 3-6 months. However, patients considered that some of the questions are ambiguous and too technical. Patients reported that it would be useful to include additional items relating to daily wound care, compression bandaging, and dressings. Clinicians reported that the VLU-QoL instrument was too long and required restructuring to facilitate utility in practice. A conceptual framework for HRQoL in VLUs included traditional HRQoL components and VLU-specific issues. Overall, the VLU-QoL was well accepted, although changes to make it more concise, comprehensive, and to clearly reflect consumers' perspectives were lacking. The proposed conceptual framework will inform the development of a new PROM for use by clinicians and patients in clinical settings.
- Published
- 2019
17. Current practices and standards regarding provision of information to women newly diagnosed with DCIS: a national survey
- Author
-
Claudia Rutherford, Angela Ju, Di Treble, Lisa Morstyn, and Madeleine King
- Subjects
Oncology (nursing) - Published
- 2021
18. Développement et validation du questionnaire Flare-OA pour la mesure d’une poussée d’arthrose du genou et de la hanche
- Author
-
Marita Cross, J.-F. Maillefert, Elisabeth Spitz, Camille Ricatte, Lyn March, T. Buttel, Claudia Rutherford, Jonathan I. Epstein, Camille Alleyrat, G. Hawker, Y. Traore, Bruno Fautrel, Leigh F. Callahan, L.K. King, David J. Hunter, and Francis Guillemin
- Subjects
Epidemiology ,Public Health, Environmental and Occupational Health - Abstract
Etat de la question L’objectif etait de developper un questionnaire mesurant les poussees dans l’arthrose et evaluer ses proprietes psychometriques. Materiel et methodes Les items ont ete generes a partir d’entretiens semi-structures et d’un groupe de discussion (patients, cliniciens) en utilisant une approche bilingue. La selection des items a ete faite avec une methode Delphi. Des patients arthrosiques en Australie, en France et aux Etats-Unis ont rempli les questionnaires electroniques. L’analyse factorielle et l’approche du contenu ont ete utilisees pour reduire les items et determiner la validite structurelle. Le questionnaire obtenu (score de 0 a 100) a ete teste pour la coherence interne, la validite convergente et discriminante. Resultats Depuis les 180 items initialement generes, la methode Delphi et comites d’experts ont selectionne 33 items. Le questionnaire comportait cinq domaines et utilisait les modalites de reponse (0 = Pas du tout a 10 = Absolument). Parmi les 398 patients (âge moyen 64 ans) ayant rempli le questionnaire, 70,4 % etaient des femmes et 86,7 % avait une arthrose du genou. L’analyse factorielle confirmatoire retenait un modele a 19 items (RMSEA = 0,06 ; SRMR = 0,04 ; CFI = 0,96 et TLI = 0,94). L’alpha de Cronbach etait > 0,9 pour les cinq domaines et l’ensemble du questionnaire. La correlation entre Flare-OA et les autres instruments etaient conformes aux previsions. La difference de score (31,8) entre les patients avec et sans poussee etait significative (p Conclusion Flare-OA est un instrument valide et fiable, rapporte par les patients atteints d’arthrose du genou/hanche, qui permet d’evaluer la frequence et la gravite des poussees d’arthrose en recherche clinique ( Tableau 1 , Tableau 2 , Tableau 3 ).
- Published
- 2021
19. Using feedback tools to enhance the quality and experience of care
- Author
-
Jan R, Boehnke and Claudia, Rutherford
- Subjects
Surveys and Questionnaires ,Quality of Life ,Humans ,Quality Improvement ,Feedback - Published
- 2021
20. Body Image Scale: Evaluation of the Psychometric Properties in Three Indian Head and Neck Cancer Language Groups
- Author
-
Chindhu Shunmugasundaram, Haryana M. Dhillon, Phyllis N. Butow, Puma Sundaresan, Mahati Chittem, Niveditha Akula, Surendran Veeraiah, Nagraj Huilgol, and Claudia Rutherford
- Subjects
General Psychology - Abstract
BackgroundBody image is a subjective concept encompassing a person’s views and emotions about their body. Head and neck cancer (HNC) diagnosis and treatment affects several psychosocial concepts including body image. Large numbers of HNC patients are diagnosed each year in India but there are no suitable measures in regional languages to assess their body image. This study assessed the psychometric properties of the Body Image Scale (BIS), a measure suitable for clinical and research use in HNC populations, translated into Tamil, Telugu and Hindi and compared body image distress between language groups.MethodsTranslated versions of BIS were completed by HNC patients recruited from three cancer centers across India one time only. Psychometric evaluation was conducted including factor analysis using principal component analysis and internal consistency reliability using Cronbach’s alpha. Patients completed the EORTC Quality of Life Questionnaire (QLQ) C-30 and EORTC QLQ HN-35 measures to enable exploration of convergent and discriminant validity. ANOVA was used to calculate difference in mean values for body image.ResultsOur sample included 621 HNC patients (Tamil = 205, Telugu = 216, Hindi = 200). Factor analysis revealed a one-factor solution and Cronbach’s alpha coefficients ranged between 0.891 and 0.969 indicating good reliability. Hypothesized correlations between similar and different constructs were as expected, supporting construct validity. On the BIS, we found a statistically significant difference (F = 11.0954, P < 0.05) between means of Tamil, Telugu, and Hindi groups, with higher body image scores in Telugu (M = 12.86; SD = 7.65) and Hindi groups (M = 12.52; SD = 7.36) indicating more symptoms/body image distress, when compared to Tamil population (M = 9.28; SD = 10.04).ConclusionThe reliability and validity of the three translated Indian versions of the BIS were maintained, providing a method for assessing body image of HNC population worldwide speaking Tamil, Telugu, and Hindi across the illness trajectory.
- Published
- 2021
21. Perceived benefits and limitations of using patient-reported outcome measures in clinical practice with individual patients: a systematic review of qualitative studies
- Author
-
Madeleine King, Angela Ju, Rachel Campbell, and Claudia Rutherford
- Subjects
medicine.medical_specialty ,business.industry ,Public health ,Public Health, Environmental and Occupational Health ,MEDLINE ,Qualitative property ,Prom ,Data extraction ,Nursing ,medicine ,Quality of Life ,Humans ,Patient-reported outcome ,Patient Reported Outcome Measures ,business ,Goal setting ,Qualitative Research ,Qualitative research - Abstract
Patient-reported outcome measures (PROMs) are increasingly used in clinical settings to inform individual patient care. In-depth understanding of end-users’ experiences may help identify factors that promote or hinder their use in clinical decision-making. We aimed to examine stakeholder perceptions of the utility of using PROMs in clinical practice based on real-life experience. Systematic review searching Medline, Embase and PsychINFO from inception to May 2021. Qualitative studies examining patients’ and/or clinicians’ experiences of using PROMs in clinical settings were included. Study screening and data extraction were performed by two independent reviewers. Qualitative data from included studies was analysed thematically. Of 2388 abstracts retrieved, 52 articles reporting 50 studies met eligibility. Five key benefits were identified: (1) promotes active patient involvement (enables goal setting and discussion of sensitive topics); (2) enhances the focus of consultations (prioritizes patient needs); (3) improves quality of care (enables tailored, holistic care and prompts action); (4) enables standardized monitoring of patient outcomes; and (5) enhances the patient–clinician relationship (provides reassurance). Perceived limitations included the capacity of PROMs to shift the focus of consultations; inaccurately estimate problems; raise unrealistic expectations for care; inhibit patient–clinician interaction; lack clinically meaningful information; and not be suitable for all patients. Both patients and clinicians reported benefits of using PROMs across diverse health conditions and clinical settings, but also highlighted several limitations. These limitations shed some light on why PROM use may not always improve patient outcomes and provide considerations for the design and implementation of future PROM initiatives.
- Published
- 2021
22. A Quality-of-Life Evaluation Study Assessing Health-Related Quality of Life in Patients Receiving Medicinal Cannabis (the QUEST Initiative): Protocol for a Longitudinal Observational Study (Preprint)
- Author
-
Margaret-Ann Tait, Daniel S J Costa, Rachel Campbell, Richard Norman, Stephan Schug, and Claudia Rutherford
- Abstract
BACKGROUND Evidence supports several countries introducing legislation to allow cannabis-based medicine as an adjunctive treatment for the symptomatic relief of chronic pain, chemotherapy-induced nausea, spasticity in multiple sclerosis (MS), epileptic seizures, depression, and anxiety. However, clinical trial participants do not represent the entire spectrum of disease and health status seen in patients currently accessing medicinal cannabis in practice. OBJECTIVE This study aims to collect real-world data to evaluate health-related quality of life in patients prescribed medicinal cannabis oil and describe any differences over time, from before starting therapy to after 3 and 12 months of therapy. METHODS Adult patients newly prescribed medicinal cannabis oil by authorized prescribers and under the Special Access Schemes across Australia will be screened for eligibility and invited to participate. A sample size of 2142 is required, with a 3-month follow-up. All participants will complete the EuroQol 5-Dimension; European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-30; Depression, Anxiety, and Stress Scale-21; Patients’ Global Impression of Change; Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form (SF) version 1.0: Sleep Disturbance 8b; and PROMIS SF Fatigue 13a questionnaires. Patients with chronic pain conditions will also complete the PROMIS SF version 1.0: Pain Intensity 3a and PROMIS SF version 1.0: Pain Interference 8a. Patients with movement disorders will also complete Quality of Life in Neurological Disorders (Neuro-QoL) SF version 1.0: Upper Extremity Function (Fine Motor and Activities of Daily Living) and if chorea is indicated, the Neuro-QoL SF version 2.0: Huntington’s Disease health-related Quality of LIFE-Chorea 6a. All questionnaires will be administered at baseline, 2 weeks (titration), monthly up to 3 months, and then every 2 months up to 1 year. RESULTS Recruitment commenced in November 2020. By June 2021, 1095 patients were screened for the study by 69 physicians in centers across 6 Australian states: Australian Capital Territory, New South Wales, Queensland, South Australia, Victoria, and Western Australia. Of the patients screened, 833 (39% of the target sample size) provided consent and completed baseline questionnaires. Results are expected to be published in 2022. Results of this study will show whether patient-reported outcomes improve in patients accessing prescribed medicinal cannabis from baseline to 3 months and whether any changes are maintained over a 12-month period. This study will also identify differences in improvements in patient-reported outcomes among patients with different chronic conditions (eg, chronic pain, MS, epilepsy, Parkinson disease, or cancer). CONCLUSIONS This protocol contains detailed methods that will be used across multiple sites in Australia. The findings from this study have the potential to be integral to treatment assessment and recommendations for patients with chronic pain and other health indicators for accessing medicinal cannabis. CLINICALTRIAL Australian New Zealand Clinical Trials Registry: ANZCTRN12621000063819; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380807&isReview=true INTERNATIONAL REGISTERED REPORT DERR1-10.2196/32327
- Published
- 2021
23. Patient-reported anxiety and depression measures for use in Indian head and neck cancer populations: a psychometric evaluation
- Author
-
Haryana M. Dhillon, Phyllis Butow, Mahati Chittem, Surendran Veeraiah, Niveditha Akula, Claudia Rutherford, Puma Sundaresan, and Chindhu Shunmugasundaram
- Subjects
business.industry ,Research ,Construct validity ,Health Informatics ,Disfigurement ,language.human_language ,Telugu ,Patient Health Questionnaire ,03 medical and health sciences ,0302 clinical medicine ,Health Information Management ,Convergent validity ,Cronbach's alpha ,030220 oncology & carcinogenesis ,Tamil ,language ,Medicine ,Anxiety ,030212 general & internal medicine ,Public aspects of medicine ,RA1-1270 ,medicine.symptom ,business ,Clinical psychology - Abstract
Background Head and neck cancers (HNC) are one of the most traumatic forms of cancer because they affect essential aspects of life such as speech, swallowing, eating and disfigurement. HNCs are common in India, with over 100,000 cases being registered each year. HNC and treatment are both associated with considerable anxiety and depression. With increasing multinational research, no suitable measures in Indian languages are available to assess anxiety and depression in Indian HNC patients. This study evaluated the psychometric properties of cross-culturally adapted versions of Zung’s self-rating Anxiety Scale (SAS) and the Patient health questionnaire – 9 (PHQ-9) in Tamil, Telugu and Hindi speaking Indian HNC populations. Methods HNC patients were recruited from three tertiary cancer centres in India. Patients completed the cross-culturally adapted versions of SAS and PHQ-9. We assessed targeting, scaling assumptions, construct validity (exploratory and confirmatory factor analyses), convergent validity, and internal consistency reliability. Results The study sample included 205 Tamil, 216 Telugu and 200 Hindi speaking HNC patients. Exploratory and confirmatory factor analyses indicated a two-factor solution for PHQ-9 and four-factor solution for SAS in all three languages. Cronbach’s alpha coefficients ranged between 0.717 and 0.890 for PHQ-9 and between 0.803 and 0.868 for SAS, indicating good reliability. Correlations between hypothesized scales were as expected providing evidence towards convergent validity. Conclusions This first psychometric evaluation of the measurement properties of Tamil, Telugu and Hindi versions of the SAS and PHQ-9 in large, Indian HNC populations supported their use as severity and outcome measures across the disease and treatment continuum.
- Published
- 2021
24. Patient-reported outcomes as predictors of survival in patients with bowel cancer: a systematic review
- Author
-
Madeleine King, Rachel Campbell, Claudia Rutherford, and Katherine M. White
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Colorectal cancer ,Disease ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,Internal medicine ,medicine ,Humans ,In patient ,Patient Reported Outcome Measures ,business.industry ,030503 health policy & services ,Public Health, Environmental and Occupational Health ,Univariate ,Patient survival ,Prognosis ,medicine.disease ,humanities ,Study Characteristics ,Mood ,030220 oncology & carcinogenesis ,Quality of Life ,Female ,Colorectal Neoplasms ,0305 other medical science ,business - Abstract
The prognostic value of patient-reported outcomes (PROs) has been determined in some cancers, but a focussed review in colorectal cancer (CRC) has not yet been conducted. We systematically reviewed PRO predictors of CRC patient survival. We searched four electronic databases (from inception to May 2018), reference lists and professional organisations to identify studies reporting pre-treatment PRO predictors of overall survival (OS) or progression-free survival (PFS) in CRC identified through univariate or multivariate models. Two reviewers independently applied inclusion criteria and extracted data on study characteristics, median and 1-year survival rates, PROs assessed and model results. In 25 of 27 studies (n = 12,544), at least one PRO was significantly associated with survival. Physical functioning, fatigue, pain and appetite loss predicted OS more often than other PROs in metastatic disease (19/27 studies). One study explored PRO predictors in early-stage CRC, finding emotional well-being and mood predicted OS. In mixed-stage samples (7/27 studies), physical functioning predicted OS more often than other PROs. Few studies modelled PFS, for which few PROs had predictive value. Physical and psychological functioning, pain, fatigue and appetite loss had prognostic significance above and beyond clinical predictors in CRC. Routine monitoring of these PROs may allow earlier detection and amelioration of problems, which may improve quality of life and perhaps extend survival. More research is needed to determine prognostic value of PROs in early-stage CRC, and prognostic significance of changes in PRO scores.
- Published
- 2019
25. A systematic review of body image measures for people diagnosed with head and neck cancer (HNC)
- Author
-
Puma Sundaresan, Claudia Rutherford, Haryana M. Dhillon, Phyllis Butow, and Chindhu Shunmuga Sundaram
- Subjects
medicine.medical_specialty ,Databases, Factual ,Psychometrics ,Body Image Scale ,Prom ,Conceptual schema ,03 medical and health sciences ,0302 clinical medicine ,Cronbach's alpha ,Body Image ,Content validity ,Humans ,Medicine ,Patient Reported Outcome Measures ,030212 general & internal medicine ,business.industry ,Nursing research ,Head and neck cancer ,medicine.disease ,female genital diseases and pregnancy complications ,Readability ,Oncology ,Head and Neck Neoplasms ,030220 oncology & carcinogenesis ,Physical therapy ,business - Abstract
Head and neck cancer (HNC) is a relatively common cancer which causes a significant health burden, impacting individuals physically and psychologically. HNC treatment may result in facial disfigurement, eating and communication difficulties, and body image disturbances. We aimed to (1) identify HNC-specific patient-reported outcome measures (PROMs) used to assess body image, (2) evaluate their conceptual coverage, (3) appraise their development process and psychometric properties, and (4) determine appropriate body image PROM(s) for use in the HNC setting. Online databases were searched (July 2007–July 2017) for studies that assessed body image in patients with HNC. Studies were screened for eligibility. In addition, we searched three PROM databases for relevant PROMs. From available body image frameworks, we compiled a conceptual schema consisting of 18 clinically relevant body image issues important in the HNC setting, against which PROMs were assessed. Selected measures were appraised for psychometric characteristics, content, and readability. A total of 245 records were retrieved. 18 studies with PROMs met our inclusion criteria, reporting eight PROMs. The PROM databases searched yielded 62 measures. After screening, eleven measures were short-listed and appraised. The Derriford Appearance Scale (DAS)-59, DAS-24, and body image scale (BIS) cover > 55% of issues within the body image conceptual schema; were developed based on literature, patient interviews, and clinician opinions; and have evidence of internal consistency (Cronbach alpha > 0.7), validity, and responsiveness. We recommend the DAS-24 and BIS as having adequate coverage of HNC-related issues, and suitable for use in future research.
- Published
- 2019
26. Comparison of generic and disease‐specific measures in their ability to detect differences in pressure ulcer clinical groups
- Author
-
Howard Collier, Susanne Coleman, Elizabeth McGinnis, Jane Nixon, Julia Brown, Lyn Wilson, Rachael Gilberts, Isabelle L Smith, Sarah Brown, Daniel S.J. Costa, Claudia Rutherford, and Rachel Campbell
- Subjects
Adult ,Male ,Disease specific ,medicine.medical_specialty ,MEDLINE ,Psychological intervention ,Context (language use) ,Dermatology ,Group comparison ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Quality of life (healthcare) ,Surveys and Questionnaires ,Outcome Assessment, Health Care ,Health care ,medicine ,Humans ,Patient Reported Outcome Measures ,Aged ,Aged, 80 and over ,Pressure Ulcer ,Wound Healing ,business.industry ,Reproducibility of Results ,Middle Aged ,Skin Care ,Physical therapy ,Female ,Surgery ,Research questions ,business - Abstract
Patient-reported outcomes can be included as end points in pressure ulcer (PU) intervention trials to provide information to inform decision-making and improve the lives of patients. However, the challenge for researchers and clinicians is identifying and choosing an appropriate instrument for each particular application that suits their research questions and clinical context. To provide researchers and clinicians with the information needed to inform choice of patient-reported outcome measures, we compared a generic and disease-specific measures' ability to discriminate between clinical groups known to differ, and determined their responsiveness to change. We performed analyses on a subset of patients recruited to the PRESSURE 2 trial that completed the pressure ulcer quality of life instrument-prevention version (PU-QOL-P) and Short Form 12 Questionnaire (SF12) measures at baseline and 30-day posttreatment. Known-group validity and responsiveness-to-change analyses were conducted. The analysis sample consisted of 617 patients that completed both measures at baseline. Known-group validity revealed that some PU-QOL-P symptoms and function scales differentiated between people with category 2 PUs and those without PUs. A less meaningful pattern of results was observed for the SF12 scales, suggesting that the PU-QOL-P is more sensitive to differences between PU and non-PU populations. Responsiveness analysis revealed that the PU-QOL-P was more responsive in detecting disease severity than the SF12. The PU-QOL-P provides a standardized method for assessing PU-specific symptoms and functioning outcomes and is suitable for quantifying the benefits of PU interventions from the patient's perspective. Generic measures are useful for group comparisons of global quality of life domains. Choice of measure for each particular application should be determined by the purpose of the measurement and the information required.
- Published
- 2019
27. Trials with proxy-reported outcomes registered on the Australian New Zealand Clinical Trials Registry (ANZCTR)
- Author
-
Rebecca, Mercieca-Bebber, Douglas, Williams, Margaret-Ann, Tait, Claudia, Rutherford, Lucy, Busija, Natasha, Roberts, Michelle, Wilson, Chindhu, Shunmuga Sundaram, and Jessica, Roydhouse
- Subjects
Male ,Australia ,Public Health, Environmental and Occupational Health ,Proxy ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Quality of Life ,Humans ,Female ,Patient Reported Outcome Measures ,Registries ,030212 general & internal medicine ,New Zealand - Abstract
A proxy is someone other than a patient who reports a patient's outcomes as if they are the patient. Due to known discordance with patient reports, proxies are often not recommended in clinical trials; however, proxies may be needed in certain research contexts. We aimed to identify and describe trials registered on the Australian New Zealand Clinical Trials Registry (ANZCTR) with proxy-reported endpoints.ANZCTR was systematically searched from inception (2005) to 31 March 2017 for trials with proxy-reported endpoints. Primary and secondary endpoints for each trial retrieved by the search were individually coded (proxy-reported: yes/no), and trials with confirmed proxy-reported endpoints were included in the analysis.Of 13,666 registered trials, 469 (3.4%) included a proxy-reported endpoint (867 individual proxy-reported endpoints in total: 62% family member proxy, 22% health professional). Proxy endpoint inclusion did not significantly increase over time (r = 0.18, p = 0.59). Mental health (11.5%), stroke (10.3%) and neurological (8.3%) trials had the highest proportion of trials using proxies. Of the 469 trials, 123 (26.2%) studies involved paediatric patients.Proxy-reported endpoints are included in a small but notable number of studies, which may indicate other types of outcomes are used for patients unable to self-report, or that these patients are under-researched.
- Published
- 2018
28. Enabling cross-cultural data pooling in trials: linguistic validation of head and neck cancer measures for Indian patients
- Author
-
Puma Sundaresan, Chindhu Shunmugasundaram, Claudia Rutherford, Haryana M. Dhillon, and Phyllis Butow
- Subjects
Cross-Cultural Comparison ,India ,Linguistic validation ,Telugu ,03 medical and health sciences ,0302 clinical medicine ,Surveys and Questionnaires ,medicine ,Humans ,Psychological testing ,Translations ,Equivalence (measure theory) ,Hindi ,030503 health policy & services ,Public Health, Environmental and Occupational Health ,Linguistics ,language.human_language ,Distress ,Head and Neck Neoplasms ,030220 oncology & carcinogenesis ,Tamil ,language ,Quality of Life ,Anxiety ,medicine.symptom ,0305 other medical science ,Psychology ,Clinical psychology - Abstract
Head and neck cancers (HNC) and their treatments cause dysfunction and distress. Ongoing psychological assessment using disease-specific patient-reported measures may optimize clinical decision-making, facilitate interventions to reduce psychosocial burden. As most such measures are developed in English, non-English speaking patients are disadvantaged. This study translated HNC-specific measures (Body Image Scale, Patient Concerns Inventory, Zung’s Self-Rating Anxiety and Depression Scales and Patient Health Questionnaire-9) into three Indian languages (Hindi, Tamil and Telugu) and linguistically validated them. Translation followed established guidelines on translation and linguistic validation of measures. Process involved two independent forward translations, reconciliation, two independent backward translations by bilingual experts, and cognitive debriefing interviews with nine healthcare professionals (HCPs) and 29 HNC patients. Translated versions were compared with the original versions for semantic, cultural and conceptual equivalence. Overall, 17 Hindi items, 19 Tamil items and 13 Telugu items were identified to have semantic, cultural and/or conceptual issues. These were resolved to achieve equivalence with the original measures. Interviews with HCPs indicated that equivalent terms for words such as anxiety, panicky, sexuality, and self-conscious might be difficult to understand. Interviews with patients indicated all items were understandable, easy, sensitive, unambiguous and relevant. Hence, no further revisions were made. The translated Hindi, Tamil and Telugu versions of the Body image scale, Patient concerns inventory, Zung’s self-rating anxiety and depression scales and Patient health questionnaire-9 measures are conceptually and linguistically validated and equivalent with the original English versions. Psychometric validation of these measures with relevant patient populations is needed.
- Published
- 2021
29. How is quality of life defined and assessed in published research?
- Author
-
Daniel S J, Costa, Rebecca, Mercieca-Bebber, Claudia, Rutherford, Margaret-Ann, Tait, and Madeleine T, King
- Subjects
Health Status ,Surveys and Questionnaires ,Quality of Life ,Humans ,Patient Reported Outcome Measures - Abstract
To ensure clarity in communication in the field of quality of life research, and meaningful use of 'quality of life' as a research outcome, requires two things: awareness that there is a range of conceptualisations and definitions of 'quality of life', and for any particular study, consistency between the way the term is defined and operationalised in that setting. We aimed to identify how frequently research articles described (HR)QOL as a construct of interest, how frequently they referred to "patient-reported outcome (measures)", which patient-reported outcome measures were used, and how (HR)QOL was defined.We reviewed all Quality of Life Research articles published in 2017 and recorded whether they described health-related quality of life or quality of life as constructs of interest, and/or mentioned the term(s) patient-reported outcome (measures). We recorded definitions of (HR)QOL stated and questionnaires used. We classified articles according to constructs assessed and instruments used, and examined whether articles citing the same definition used the same questionnaires.We reviewed 300 articles; 65% stated that (HR)QOL was a construct of interest, 27% mentioned patient-reported outcome (measures), and 20% mentioned neither. Fifty-one articles provided definitions of (HR)QOL, citing 66 sources, with 11 definitions cited more than once. PROMIS, SF, EQ-5D, and EORTC instruments were the most commonly used. The only definition and questionnaire consistently used together were the WHO definitions/instruments.These results demonstrate considerable heterogeneity in the definition and operationalisation of (HR)QOL, between and within studies. This limits meaningful interpretation of (HR)QOL scores and complicates literature searches. Investigators should define constructs and select instruments aligned with their definitions.
- Published
- 2021
30. Registered Reports at 'Quality of Life Research'
- Author
-
Jan R. Boehnke and Claudia Rutherford
- Subjects
medicine.medical_specialty ,Medical education ,business.industry ,Public health ,Public Health, Environmental and Occupational Health ,medicine ,MEDLINE ,business ,Quality of Life Research - Published
- 2020
31. Patient-reported outcomes in non-muscle invasive bladder cancer: a mixed-methods systematic review
- Author
-
Claudia, Rutherford, Manish I, Patel, Margaret-Ann, Tait, David P, Smith, Daniel S J, Costa, Shomik, Sengupta, and Madeleine T, King
- Subjects
Male ,Urinary Bladder Neoplasms ,Quality of Life ,Humans ,Female ,Patient Reported Outcome Measures - Abstract
Non-muscle invasive bladder cancer (NMIBC) is a chronic condition requiring repeated treatment and endoscopic examinations that can occur life-long. In this context, patient-reported outcomes (PROs) are important considerations to patients and managing clinicians. We undertook a systematic review to synthesise PRO results relevant to NMIBC treatment to explore trajectories overtime and differences between treatment options.We searched databases AMED, MEDLINE, EMbase, PsycINFO, Web of Knowledge and Scopus (inception to 5th December 2019), reference lists and contacted key authors to identify studies that reported PROs after NMIBC treatment. Two reviewers independently applied inclusion and quality criteria and extracted findings. Results for PROs were synthesised for treatment groups across three time periods: acute/during induction therapy; during maintenance therapy; and long-term follow-up (1 year).Of 3193 papers screened, 29 were eligible. These provided evidence about induction treatment effects, but few reported maintenance or long-term evidence, and evidence about differences between NMIBC treatment options was lacking. A range of symptoms (pain in bladder area, urinary frequency and urgency, pain or burning during urination) were commonly experienced during and soon after treatment for NMIBC. Less common symptoms included fatigue, disrupted sleep and gastrointestinal problems.Treatments for NMIBC can cause symptoms and functional impairment during the acute treatment phase and reduce quality of life. Clinicians should be aware of these impairments to prepare patients for short-term sequelae and enable those with treatment options to exercise preferences in choosing among them. However, gaps in current evidence limit our understanding of PRO trajectories from diagnosis through to long-term survivorship and treatment effects.
- Published
- 2020
32. What are the optimal measures to identify anxiety and depression in people diagnosed with head and neck cancer (HNC): a systematic review
- Author
-
Claudia Rutherford, Haryana M. Dhillon, Puma Sundaresan, Chindhu Shunmugasundaram, and Phyllis Butow
- Subjects
medicine.medical_specialty ,MEDLINE ,Health Informatics ,Review ,Psychological distress ,Prom ,Anxiety ,03 medical and health sciences ,0302 clinical medicine ,Health Information Management ,Quality of life ,Medicine ,030212 general & internal medicine ,Head and neck cancer ,Depression (differential diagnoses) ,Depression ,business.industry ,lcsh:Public aspects of medicine ,lcsh:RA1-1270 ,Patient reported outcome measures ,Checklist ,Distress ,030220 oncology & carcinogenesis ,Systematic review ,Physical therapy ,Patient-reported outcome ,medicine.symptom ,business - Abstract
Background A cancer diagnosis is potentially life-threatening, likely causing distress and uncertainty, which may be psychologically debilitating. Depression and anxiety are commonly underdiagnosed and undertreated in cancer patients. Head and neck cancer (HNC) patients face particular challenges that may contribute to distress. This review aims to: i) identify patient reported outcome measures (PROMs) designed to assess anxiety and depression in HNC; and ii) determine their suitability for use in research and clinical practice to screen patients. Methods We searched five electronic databases between July 2007 to July 2019 for studies assessing anxiety and depression in HNC patients. Searches were limited to this period to account for advances in cancer treatment. Records were screened for eligibility by one reviewer and 10% cross-checked by a second across all stages of the review. In addition to the electronic searches, PROM databases were searched for additional measures of anxiety and depression. All retrieved PROMs were mapped against Diagnostic and Statistical Manual-5 criteria for anxiety and depression to assess content coverage. Then, their psychometric properties appraised against the COSMIN checklist. Results Electronic searches identified 98 records, from which five anxiety and eight depression measures were retrieved. PROM database searches retrieved an additional four anxiety and four depression measures; a total of nine anxiety and 12 depression measures were appraised. Content coverage of anxiety measures ranged from 50% to 75% and depression measures from 42% to 100%. Demonstration of psychometric properties against COSMIN criteria ranged from 57% to 71% for anxiety measures (three PROMs > 70%) and from 29% to 86% for depression measures (nine PROMs > 70%). Three anxiety and seven depression measures had established clinical cut-offs in cancer populations. Conclusions The Patient Health Questionnaire-9, Zung Self-rating Depression and Zung Self-rating Anxiety Scales demonstrated good content coverage along with excellent psychometric properties, and thus were considered the most suitable PROMs to assess psychological distress in HNC populations. It is important to have PROMs assessing psychological distress that capture a comprehensive set of subjective symptoms. The identified PROMs will help researchers and health professionals in clinical-decision making, thereby potentially improving quality of life in HNC patients.
- Published
- 2020
33. 47 Views of healthcare professionals on issues around ductal carcinoma in situ detected through an expanded mammography screening program
- Author
-
Andrew J. Spillane, Kirsten McCaffery, Christobel Saunders, Brooke Nickel, Nehmat Houssami, Claudia Rutherford, Elizabeth Wylie, Alexandra Barratt, Jolyn Hersch, Geraldine Robertson, Kirsty Stuart, and Jesse Jansen
- Subjects
medicine.medical_specialty ,Health professionals ,business.industry ,Incidence (epidemiology) ,Disease ,Ductal carcinoma ,medicine.disease ,Harm ,Breast cancer ,Family medicine ,Life expectancy ,medicine ,Overdiagnosis ,skin and connective tissue diseases ,business - Abstract
Introduction The incidence of ductal carcinoma in situ (DCIS) has increased greatly since the introduction of organised breast screening. Because DCIS encompasses a spectrum of disease, including some indolent lesions that may not progress, there is growing concern about overdiagnosis and overtreatment. Women aged 70–74 years are included in the expanded age range now targeted for population screening in Australia, and this group may differ from younger women in terms of potential for benefit and harm. We aimed to understand healthcare professionals’ views about DCIS. Methods Doctors and nurses working with DCIS patients in diverse settings around Australia and New Zealand were recruited via professional organisations and contacts. We conducted semi-structured telephone interviews with 26 healthcare professionals (10 breast surgeons, 6 radiation oncologists, 3 breast physicians, 7 breast care nurses). Topics included current practice and future directions for managing DCIS, issues around patient communication, and benefits and harms of screening women over 70. Interviews were audio-recorded, transcribed, and analysed thematically. Results Many participants felt the screening age extension was justified because life expectancy has increased. They suggested that older women often interpret their screening invitations stopping as an indication that they are no longer at risk of breast cancer. On the other hand, many clinicians believed that continuation of screening should depend on individual life expectancy given the risk of harm, for example through overdiagnosis and overtreatment of low-grade DCIS among older women in poor health. Some participants emphasised that women should be informed about potential consequences of screening, including benefits and harms, and involved in deciding whether to be screened. Discussion Doctors and nurses who work with DCIS patients offer a valuable perspective on current issues around the detection and management of DCIS. We will discuss the key findings and their implications for future research, screening and clinical practice.
- Published
- 2019
34. Systematic review of clinical practice guidelines for colorectal and anal cancer: the extent of recommendations for managing long-term symptoms and functional impairments
- Author
-
Claudia Rutherford, Madeleine King, Katherine M. White, and Lisette M. Wiltink
- Subjects
medicine.medical_specialty ,Consensus ,Databases, Factual ,Psychological intervention ,Long-term side effects ,Review Article ,03 medical and health sciences ,0302 clinical medicine ,Cancer Survivors ,Survivorship curve ,medicine ,Anal cancer ,Humans ,030212 general & internal medicine ,Healthy Lifestyle ,Long-term functioning ,Intensive care medicine ,Exercise ,business.industry ,Nursing research ,Cancer ,Guideline ,Long-term symptoms ,medicine.disease ,Anus Neoplasms ,Colorectal cancer ,Distress ,Sexual dysfunction ,Oncology ,030220 oncology & carcinogenesis ,Practice Guidelines as Topic ,medicine.symptom ,business ,Colorectal Neoplasms ,Clinical practice guidelines - Abstract
Purpose Due to increasing numbers of colorectal and anal cancer survivors, more individuals are living with long-term symptoms after treatment. A systematic review was undertaken to assess the extent to which practice guidelines for colorectal and anal cancer provide recommendations for managing long-term symptoms and functioning impairments. Methods Four electronic databases and websites of 30 international cancer societies were searched for clinical practice guidelines, consensus statements, or best practice recommendations for colorectal or anal cancer. Quality of included guidelines was evaluated with the Appraisal of Guidelines for Research & Evaluation II tool. Results were narratively summarized. Results We included 51 guidelines or consensus statements. Recommendations for managing long-term symptoms or functioning impairments were reported in 13 guidelines (25.4%). All 13 recommend a healthy lifestyle, diet, body weight, and physical activity. The ASCO Colorectal Cancer Survivorship Care Guideline is the most comprehensive, including interventions targeting sexual and bowel function to pain and cognitive issues, and also highlights limited evidence for informing management strategies. Other guidelines recommend treating incontinence, chronic diarrhea, and distress, and stress the need for greater awareness for sexual dysfunction, survivorship clinics, and referrals to specific supportive care interventions. Conclusions Few clinical practice guidelines include recommendations for managing long-term symptoms and functioning impairments. It is unclear if this is due to limited evidence or absence of management strategies and interventions. Clear recommendations for managing long-term symptoms and functioning to help health professionals in supporting colorectal and anal cancer survivors are needed.
- Published
- 2019
35. Questionnaire Flare-OA mesurant la poussée d’arthrose du genou et de la hanche : évaluation des propriétés psychométriques
- Author
-
M. Lyn, Elisabeth Spitz, David J. Hunter, Camille Alleyrat, Y. Traore, R. Camille, Bruno Fautrel, L.K. King, Jonathan I. Epstein, J.-F. Maillefert, Gillian A. Hawker, Thomas Buttel, Claudia Rutherford, Marita Cross, Leigh F. Callahan, and Francis Guillemin
- Subjects
Epidemiology ,Public Health, Environmental and Occupational Health - Abstract
Introduction L’arthrose des membres inferieurs est une maladie frequente et invalidante, dont l’evolution se fait par poussees de duree variable et de survenue imprevisible, difficile a mettre en evidence pour le medecin. Le point de vue des patients est essentiel. L’objectif etait d’evaluer les proprietes psychometriques d’un auto-questionnaire en developpement pour mesurer les poussees dans l’arthrose. Methodes Utilisant une version bilingue du questionnaire (33 items, reponse sur echelle numerique 0 a 10), une etude multicentrique (Australie, France et Etats-Unis) a ete conduite en ligne chez des patients souffrant d’arthrose de la hanche et du genou. Le nombre de sujets requis pour estimer les proprietes psychometriques etait de 330 sujets, en tenant compte du nombre total d’items. Sur la base d’une definition internationale validee des cinq domaines composant une poussee, une analyse factorielle confirmatoire associee a l’analyse de contenu ont ete utilisees pour reduire le nombre d’items et determiner la validite de structure. Le questionnaire Flare-OA obtenu (score de 0 a 100) a ete teste pour sa coherence interne, sa validite convergente et discriminante. Resultats Parmi les 398 patients (âge moyen 64 ans) ayant rempli le questionnaire, 70,4 % etaient des femmes et 86,7 % avaient une arthrose du genou. L’analyse factorielle confirmatoire a retenu un modele a 19 items (RMSEA = 0,06 ; SRMR = 0,04 ; CFI = 0,96 et TLI = 0,94). L’alpha de Cronbach etait > 0,9 pour les cinq domaines et l’ensemble du questionnaire. La correlation entre Flare-OA et les autres instruments etait conforme aux hypotheses. La validite discriminante a ete objectivee par une difference de score (31,8 ; p Conclusion Le questionnaire optimise Flare-OA (19 items) est un instrument valide et fiable qui permet d’evaluer la frequence et la gravite des poussees d’arthrose en recherche clinique.
- Published
- 2021
36. Validité de contenu d’un questionnaire en plusieurs langues pour la mesure de l’arthrose du genou et de la hanche : développement du Flare-OA
- Author
-
Elisabeth Spitz, Y. Traore, T. Durüoz, M. Sebbani, L. Adarmouch, Jonathan I. Epstein, A. Barcenilla-Wong, Bruno Fautrel, Thomas Buttel, Francis Guillemin, D. Hunter, Lyn March, Gillian A. Hawker, M. Vitaloni, Marita Cross, and Claudia Rutherford
- Subjects
Epidemiology ,Public Health, Environmental and Occupational Health - Abstract
Introduction La poussee d’arthrose du genou et de la hanche est un evenement important dans la vie quotidienne des patients et pour la recherche clinique. Une definition de la poussee a ete etablie, et un ensemble de domaines qui la caracterise a ete recemment approuve par l’OMERACT/OARSI. Aucune mesure rapportee par le patient (PRO) ne s’est focalisee sur ce phenomene de la poussee d’arthrose. L’objectif etait de developper un auto-questionnaire mesurant les poussees d’arthrose en cinq langues, en utilisant des donnees qualitatives et un consensus international Delphi. Methodes Nous avons genere des items en utilisant une approche bilingue (anglais et francais) impliquant des patients souffrant d’arthrose de hanche et de genou en Australie, en France et aux Etats-Unis, et des professionnels de sante (PS) de societes internationales (OARSI, SFR, OMERACT). La generation d’items s’est appuyee sur des entretiens individuels menes avec des patients atteints d’arthrose et des PS, et un focus group de patients. L’analyse de contenu a permis d’identifier les verbatims qui etaient importants pour les patients et les PS. Une methode de consensus Delphi a ete utilisee pour selectionner les items les plus pertinents, en accord avec l’ensemble des domaines fondamentaux identifies par l’organisation OMERACT. Une approche interculturelle utilisant les recommandations methodologiques actuelles a ete appliquee pour produire des versions espagnoles (en Espagne), turcs et arabes classiques (au Maroc) utilisant une traduction independante et un comite d’experts pour preserver la validite de son contenu. Resultats A l’issue des entretiens semi-structures avec 29 patients et 16 professionnels de sante et d’un focus group avec 10 patients, 180 items ont ete generes en francais (106) et en anglais (77). Sur la base des similitudes ou redondances, 50 items ayant une signification equivalente dans les deux langues ont ete retenus par un comite d’experts. Apres deux tours de Delphi impliquant 50 patients et 116 PS de 17 pays sur 4 continents, le questionnaire a ete reduit a 33 items (reponse 0 = pas du tout, a 10 = absolument) dans cinq domaines (douleur, gonflement, raideur, consequences des symptomes et aspects psychologiques). Ce questionnaire a ete adapte en espagnol de maniere interculturelle, en turc et en arabe classique. L’adaptation espagnole a revele un item inapproprie dans le questionnaire original qui a ete modifie en consequence dans les cinq langues. Conclusion La poussee d’arthrose est plus qu’une simple exacerbation de la douleur. Le questionnaire Flare-OA couvre tous les domaines fondamentaux recommandes par OMERACT. Une validite de contenu elevee a ete constatee dans cinq versions, originales en deux langues et adaptees en trois langues. Le questionnaire Flare-OA doit etre considere comme adapte a son objectif et pret pour l’evaluation de sa sensibilite au changement pour les essais cliniques en cinq langues.
- Published
- 2021
37. POS0270-HPR FLARE-OA QUESTIONNAIRE TO MEASURE FLARES IN OSTEOARTHRITIS OF THE KNEE AND HIP: ASSESSMENT OF ITS PSYCHOMETRIC PROPERTIES
- Author
-
Elisabeth Spitz, Camille Alleyrat, Y. Traore, Francis Guillemin, David J. Hunter, Claudia Rutherford, L. March, Leigh F. Callahan, Gillian A. Hawker, L.K. King, J.-F. Maillefert, Bruno Fautrel, Thomas Buttel, C. Ricatte, Jonathan I. Epstein, and Marita Cross
- Subjects
medicine.medical_specialty ,business.industry ,Immunology ,Measure (physics) ,Osteoarthritis ,medicine.disease ,General Biochemistry, Genetics and Molecular Biology ,law.invention ,Rheumatology ,law ,Physical therapy ,medicine ,Immunology and Allergy ,business ,Flare - Abstract
Background:Hip and knee OA is characterised by disease flares – understanding the determinants and consequences of OA flares has been hampered by lack of a standardized flare measure beyond the pain aspect. The patients point of view on the different aspect of their flares is essential.Objectives:The objective was to assess the psychometric properties of a new questionnaire for measuring the multidimensional aspect of flares in OA.Methods:Using a bilingual version of the questionnaire (33 items, response on a numeric scale, from 0 to 10), a multicentre survey (Australia, France and United States) was conducted on line with patients diagnosed with OA of the hip and/or the knee. Based on an international OMERACT/OARSI endorsed definition of the five core domains (pain, swelling, stiffness, consequences of symptoms and psychological aspects) composing a flare in OA [1], a confirmatory factorial analysis linked to the content analysis has been used to reduce the number of items and to determine the validity of the structure. The Flare-OA questionnaire (score from 0 to 100) has been tested in French and English for its internal consistency, its convergent validity with HOOS/KOOS and Mini-OAKHQOL questionnaires, and its discriminant validity.Results:Out of 398 patients (mean age 64 years old) who completed the questionnaire, 70.4% were female and 86.7% had knee OA. The confirmatory factorial analysis retained a model with 19 items (RMSEA =0.06; SRMR =0.04; CFI =0.96 and TLI = 0.94). The Cronbach Alpha was > 0.9 for the 5 domains and for the whole questionnaire. The correlations between the Flare-OA and the other instruments were in line with that hypothesis flare is related but different from other concepts usually measured. The discriminant validity was evidenced by a significant score difference (31.8; pConclusion:The optimized Flare-OA questionnaire (19 items) is a reliable and valid instrument freely available from the authors for measuring the frequency and severity of flare in knee and hip OA in clinical research.References:[1]King LK, Epstein J, Cross M, et al. Establishing the Domains of Knee and Hip Osteoarthritis (OA) Flare: A Report from the OMERACT 2020 Inaugural Virtual Consensus Vote from the Flares in OA Working Group. (Submitted)Disclosure of Interests:None declared
- Published
- 2021
38. POS0269-HPR CONTENT VALIDITY OF A MULTIPLE LANGUAGES QUESTIONNAIRE FOR MEASURING FLARE IN KNEE AND HIP OA: DEVELOPMENT OF THE FLARE-OA
- Author
-
Francis Guillemin, M. Sebbani, David J. Hunter, M. Vitaloni, Claudia Rutherford, L. March, Elisabeth Spitz, A. Barcenilla-Wong, Marita Cross, L. Adarmouch, Y. Traore, Jonathan I. Epstein, Gillian A. Hawker, Bruno Fautrel, Mehmet Tuncay Duruöz, and Thomas Buttel
- Subjects
medicine.medical_specialty ,Rheumatology ,law ,business.industry ,Immunology ,Physical therapy ,medicine ,Content validity ,Immunology and Allergy ,business ,General Biochemistry, Genetics and Molecular Biology ,Flare ,law.invention - Abstract
Background:Flare in osteoarthritis (OA) of the knee and hip (KHOA) is an important outcome for patients’ daily life and clinical research. A definition of a flare was set, and a core set of domains was recently endorsed by OMERACT/OARSI. No patient reported outcome (PRO) yet focusses on flare in OA specifically.Objectives:To develop a self-reporting instrument measuring flare in 5 languages, using qualitative methods and international Delphi consensus.Methods:We generated items using a dual-language (English and French) approach involving patients with OA from Australia, France and the United States and health care professionals (HCP) from international societies (OARSI, SFR, OMERACT). Item generation relied on semi-structured individual interviews conducted with OA patients and HCP and one focus group with patients. Content analysis allowed for identifying verbatim statements that were meaningful for patients and HCP. A Delphi consensus method was used to select the most relevant items, according to core domains set (OMERACT). A cross-cultural approach using current guidelines (1) was applied to produce Spanish (in Spain), Turkish and classical Arabic (in Morocco) versions using independent translation and expert committee to preserve its content validity.Results:From semi-structured interviews with 29 patients and 16 HCPs and one focus group with 10 patients, 180 statements in French (106) and English (77) were generated. Based on similarity or redundancy, 50 items with equivalent meaning in both languages were retained by an expert committee. After two Delphi rounds involving 50 patients and 116 HCPs from 17 countries on four continents, it was reduced to 33 items (response 0=not at all, to 10=absolutely) in five domains (pain, swelling, stiffness, consequences of symptoms and psychological aspects). This questionnaire was cross-culturally adapted into Spanish, Turkish and classical Arabic. The Spanish version uncovered one inappropriate item in the original questionnaire that was amended accordingly in all 5 languages.Conclusion:Flare is more than just an exacerbation of pain. The Flare-OA questionnaire includes all OMERACT recommended core domains. High content validity was seen in 2 original and 3 cross-culturally adapted languages. The Flare-OA should be considered as fit for purpose and evaluation of responsiveness in clinical studies in 5 languages.Disclosure of Interests:None declared
- Published
- 2021
39. What quality-of-life issues do women with ductal carcinoma in situ (DCIS) consider important when making treatment decisions?
- Author
-
Zoe Winters, Miriam M Boxer, Madeleine King, Claudia Rutherford, Phyllis Butow, Andrew J. Spillane, Joan McPherson, and Rebecca Mercieca-Bebber
- Subjects
Oncology ,medicine.medical_specialty ,Esthetics ,medicine.medical_treatment ,Decision Making ,Breast Neoplasms ,Health literacy ,03 medical and health sciences ,Antineoplastic Agents, Immunological ,0302 clinical medicine ,Breast cancer ,Quality of life ,Surgical oncology ,Surveys and Questionnaires ,Internal medicine ,Ductal carcinoma in situ (DCIS) ,Body Image ,medicine ,Humans ,Pharmacology (medical) ,Radiology, Nuclear Medicine and imaging ,030212 general & internal medicine ,skin and connective tissue diseases ,Mastectomy ,Radiotherapy ,business.industry ,Australia ,Fear ,General Medicine ,Middle Aged ,Trastuzumab ,Ductal carcinoma ,medicine.disease ,Combined Modality Therapy ,Health Literacy ,Radiation therapy ,Carcinoma, Intraductal, Noninfiltrating ,030220 oncology & carcinogenesis ,Disease Progression ,Quality of Life ,Female ,Self Report ,business - Abstract
To explore quality-of-life (QOL) issues considered important when deciding on treatment for ductal carcinoma in situ (DCIS). Breast Cancer Network of Australia members diagnosed with DCIS in the past 5 years (self-identified) participated in an online survey (Sep–Nov 2015). From a list of 74 QOL issues, participants selected all issues they experienced during DCIS diagnosis, treatment or recovery, then the issues they felt important to making a DCIS treatment decision, and completed the Health Literacy Questionnaire (HLQ). Associations between QOL issues and self-reported treatment received were assessed with χ 2 tests. The primary analysis included 38 participants treated with breast-conserving surgery (n = 15), mastectomy (n = 23), and/or radiotherapy (n = 14). Fatigue-related symptoms (82%) and “fear of progression” (50%) were the most frequently-experienced issues. When deciding on DCIS treatment, the most important consideration was “fear of progression” (50%). A higher proportion of mastectomy (compared to non-mastectomy) patients considered “difficultly looking at yourself naked” (p = 0.03). Radiotherapy (compared to non-radiotherapy) patients were more likely to consider “feeling unwell” important (p = 0.006). Results were similar in a sensitivity analysis involving all 101 respondents (i.e., including 63 respondents who reported receiving chemotherapy, endocrine therapy, and/or Herceptin, suggesting that they may have been treated for invasive breast cancer). Health literacy was high across all nine HLQ scales. Fear of progression is a key consideration in DCIS treatment decision making for women with high health literacy. QOL treatment considerations differed by treatments received. Women diagnosed with DCIS may benefit from evidence about QOL to inform treatment decision making.
- Published
- 2017
40. Abstract P3-14-01: International validation of the EORTC patient-reported outcome measure (PROM) in breast reconstruction (BRR): The EORTC QLQ-BRECON23 evaluating the psychometric properties and clinical effectiveness
- Author
-
Anne Oberguggenburger, Zoe Winters, Giuseppe Catanuto, Michael Douek, S Hartnup, Gerhard Rumpold, Jalal Kokan, K Filcroft, Marie Panouilleres, Claudia Rutherford, Vesna Bjelic-Radisic, R. A. da Costa Vieira, MT King, Maryam Afzal, Bernhard Holzner, and Mani
- Subjects
Cancer Research ,Measure (data warehouse) ,medicine.medical_specialty ,Oncology ,Clinical effectiveness ,business.industry ,Physical therapy ,medicine ,Patient-reported outcome ,Prom ,Breast reconstruction ,business ,Surgery - Abstract
This abstract was withdrawn by the authors.
- Published
- 2017
41. Impact of weight loss interventions on patient-reported outcomes in overweight and obese adults with type 2 diabetes: a systematic review
- Author
-
Jordan Andre Martenstyn, Claudia Rutherford, and Madeleine King
- Subjects
Adult ,medicine.medical_specialty ,Adolescent ,Psychological intervention ,Type 2 diabetes ,Overweight ,03 medical and health sciences ,0302 clinical medicine ,Weight loss ,Intervention (counseling) ,Weight Loss ,medicine ,Humans ,030212 general & internal medicine ,Obesity ,Patient Reported Outcome Measures ,General Psychology ,030505 public health ,business.industry ,medicine.disease ,Psychiatry and Mental health ,Health psychology ,Diabetes Mellitus, Type 2 ,Physical therapy ,medicine.symptom ,0305 other medical science ,Sexual function ,business - Abstract
Previous reviews explored weight loss-induced metabolic changes in overweight and obese adults with type 2 diabetes (T2D) but did not report on the impact on patient-reported outcomes (PROs). This systematic review investigated the effect of weight loss interventions on weight loss and PROs in overweight and obese adults with T2D. We searched three electronic databases from inception to March 2018 for randomised controlled trials (RCTs) of weight loss interventions in overweight and obese (according to BMI) adults aged ≥ 18 years reporting changes in PROs from baseline to at least one follow-up assessment during or post-intervention. One reviewer screened abstracts, performed data extraction, and conducted the narrative synthesis, with 25% cross-checking by a second reviewer. We extracted data relating to sample characteristics, intervention and comparison conditions, weight loss, and change in PROs. We identified 540 papers of which 23 met eligibility reporting on 19 RCTs. Four types of interventions (diet, surgery, pharmacological, and multi-component lifestyle interventions) significantly reduced weight. Weight loss was consistently associated with improvements in sexual and physical function across all intervention types, with diet and multi-component lifestyle interventions producing more substantial improvements than surgical or pharmacological interventions. Findings for other PROs, such as HRQOL and depressive symptoms, were inconsistent across studies and intervention types. The four weight loss interventions can be prescribed to engender weight loss in overweight and obese adults with T2D, with multi-component lifestyle interventions generating substantial improvements in physical and sexual function, perhaps due to the potency of exercise in improving PROs.
- Published
- 2019
42. Decision coaching for people making healthcare decisions
- Author
-
Janet Jull, Sascha Köpke, Laura Boland, Angela Coulter, Sandra Dunn, Ian D Graham, Brian Hutton, Jürgen Kasper, Simone Maria Kienlin, France Légaré, Krystina B Lewis, Anne Lyddiatt, Wakako Osaka, Tamara Rader, Anne C Rahn, Claudia Rutherford, Maureen Smith, and Dawn Stacey
- Subjects
Medicine General & Introductory Medical Sciences ,education ,Pharmacology (medical) - Abstract
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To determine the effects of decision coaching when used to provide non‐directive support to help people prepare to make decisions related to their health care.
- Published
- 2019
43. Monitoring Immobilized Elderly Patients Using a Public Provider Online System for Pressure Ulcer Information and Registration (SIRUPP): Protocol for a Health Care Impact Study (Preprint)
- Author
-
Eugenio Vera-Salmerón, Claudia Rutherford, Carmen Dominguez-Nogueira, María Pilar Tudela-Vázquez, Victor J Costela-Ruiz, and Basilio Gómez-Pozo
- Abstract
BACKGROUND Pressure ulcers represent a major challenge to patient safety in the health care context, presenting high incidence (from 7% to 14% in Spain) and increased financial costs (€400-600 million/year) in medical treatment. Moreover, they are a significant predictor of mortality. The prevention of pressure ulcers in long-term care centers and patients’ own homes is proposed as a priority indicator of health care quality. Early stage risk assessment and database recording are both crucial aspects of prevention, classification, diagnosis, and treatment. OBJECTIVE This project proposes a 3-year study of immobilized patients residing in the Granada-Metropolitan Primary Healthcare District (DSGM) and monitored via the Pressure Ulcer Information and Registration System (SIRUPP, Spanish initials). The project aims to estimate the incidence of PUs among immobilized elderly patients, analyze the health-related quality of life of these patients by using the Pressure Ulcer Quality of Life (PU-QoL) instrument in a sample of 250 patients, determine the average time to complete wound healing, estimate the rate of pressure ulcers–associated mortality, and assess the predictive value of the Braden and Mini Nutritional Assessment risk measurement scales in a sample of 1700 patients. METHODS The DSGM runs SIRUPP, which is linked to patients’ electronic health records. Currently, 17,104 immobilized patients are monitored under this system. Health-related quality of life will be measured by patient self-reports using the Spanish Pressure Ulcer Quality of Life questionnaire, following cross-cultural adaptation and psychometric validation with respect to the English-language version. RESULTS The project commenced in June 2017 and is expected to conclude in April 2020. CONCLUSIONS This study addresses two main health outcomes—the time needed for wound healing and the mortality associated with pressure ulcers—both of which might be accounted for by variations in clinical practice and the health-related quality of life of patients with pressure ulcers. INTERNATIONAL REGISTERED REPOR DERR1-10.2196/13701
- Published
- 2019
44. Quality of Life in Women with Cervical Cancer
- Author
-
Claudia Rutherford, Madeleine King, Margaret-Ann Tait, Linda Mileshkin, and Rebecca Mercieca-Bebber
- Subjects
Cervical cancer ,medicine.medical_specialty ,business.industry ,medicine.disease ,humanities ,Clinical trial ,Distress ,Sexual dysfunction ,Quality of life ,Psychosexual development ,Survivorship curve ,Medicine ,medicine.symptom ,business ,Sexual function ,Intensive care medicine - Abstract
Cervical cancer and its treatments can affect quality of life in many ways, both positively and negatively, from diagnosis through to the acute treatment and survivorship phases. In research settings, the collective term used for all these impacts is health-related quality of life (HRQOL). These include psychological distress related to impairment of functioning, body image, sexual function, and fertility. Additional distress often follows surgical, radiotherapy, and chemotherapy treatments as these can cause urinary, gastrointestinal, and neurologic side effects, physical changes, and sexual dysfunction. Some side effects and changes are chronic, such as psychosexual problems after treatment. It is therefore important to assess symptoms, side effects, and various aspects of functioning, all of which impact HRQOL, during and after cervical cancer treatment. HRQOL information collected in clinical trials can complement clinical data to guide improvements in clinical practice and to counsel individual patients about the impact of treatment and assist them to make treatment decisions. Assessment of HRQOL in clinic can facilitate communication about HRQOL-related issues arising from cervical cancer treatment, alerting multidisciplinary health teams to issues requiring management. In this chapter, we introduce terminology and discuss how cervical cancer and its various treatments affect patients’ HRQOL including side effects of treatment, psychosexual problems, and fertility issues. Methods for assessing HRQOL in cervical cancer are discussed, and current ongoing clinical trials are summarised.
- Published
- 2019
45. Uterine Cervical Cancer
- Author
-
Margaret-Ann Tait and Claudia Rutherford
- Published
- 2019
46. A patient-reported pressure ulcer health-related quality of life instrument for use in prevention trials (PU-QOL-P): psychometric evaluation
- Author
-
Lyn Wilson, Susanne Coleman, Elizabeth McGinnis, Rachael Gilberts, Jane Nixon, Sarah Brown, Isabelle L Smith, Julia Brown, Claudia Rutherford, and Howard Collier
- Subjects
Adult ,Male ,Quality of life ,medicine.medical_specialty ,Activities of daily living ,Psychometrics ,Psychological intervention ,lcsh:Computer applications to medicine. Medical informatics ,Pressure ulcer ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Cronbach's alpha ,Validation ,Humans ,Medicine ,Patient Reported Outcome Measures ,030212 general & internal medicine ,Aged ,business.industry ,Research ,030503 health policy & services ,Public Health, Environmental and Occupational Health ,Reproducibility of Results ,Construct validity ,General Medicine ,Middle Aged ,Convergent validity ,Scale (social sciences) ,Symptoms ,Physical therapy ,lcsh:R858-859.7 ,Female ,0305 other medical science ,business - Abstract
Introduction Pressure ulcer-specific patient-reported outcome (PRO) instruments should be used to inform patient care and provide a strong evidence base for interventions aimed at preventing pressure ulcers. The aim was to carry out a comprehensive evaluation of the psychometric properties of a PRO instrument designed to assess symptoms and functional outcomes in patients at high-risk of developing pressure ulcers, the PU-QOL-P instrument. Methods We modified the original PU-QOL instrument to be suitable for patients at high risk of pressure ulcer development based on feedback from patients, specialist nurses and PRO methodologists. The modified PU-QOL-P instrument was administered to a sub-set of patients participating in the PRESSURE 2 trial. Patients completed PU-QOL-P and SF12 instruments at baseline, weeks 1 and 3, and 30 days post-treatment. We undertook psychometric evaluation of the modified PU-QOL-P to test scale targeting, scaling assumptions, reliability, validity and responsiveness. Results The analysis sample consisted of 617 patients that completed both instruments at baseline. We found that the PU-QOL-P instrument, consisting of nine PU-specific outcomes: three symptom and six function scales, meets established criteria for reliability, construct validity, and responsiveness. Internal consistency reliability was high with all scale Cronbach alpha > 0.795 (range 0.795–0.970). The factor analysis mostly supported the six-function scale structure. Scaling assumptions were satisfied; all item-total correlations above 0.30. Convergent validity was confirmed by significant correlations between hypothesized scales as expected. PU-QOL-P scales were responsive to change: mean scale scores from baseline to 30 days post-treatment were statistically significant for all scales apart the daily activities scale (effect sizes ranged from moderate to high). As expected, worse symptoms and functioning was observed in patients who had a category 1 or 2 PU compared to patients who did not have a PU. Conclusions The PU-QOL-P provides a standardised method for assessing pressure ulcer-specific symptoms and functional outcomes for quantifying the benefits of associated interventions from the patient’s perspective. It can be used in research with adults at risk of pressure ulcer development in all UK healthcare settings. Electronic supplementary material The online version of this article (10.1186/s12955-018-1049-x) contains supplementary material, which is available to authorized users.
- Published
- 2018
47. Patient-reported outcome measures for life participation in kidney transplantation: A systematic review
- Author
-
Bi Yang Chow, Kevin J. Fowler, Allison Tong, Quinetta Taylor, Martin Howell, Zeeshan Butt, Jayme E. Locke, Jonathan C. Craig, Angela Ju, Curie Ahn, Angelique F. Ralph, Jane C. Tan, Sheila G. Jowsey-Gregoire, Fabienne Dobbels, Michelle A. Josephson, Claudia Rutherford, and Vivekanand Jha
- Subjects
Activities of daily living ,medicine.medical_treatment ,kidney disease ,INTERNATIONAL CLASSIFICATION ,030230 surgery ,0302 clinical medicine ,QUALITY-OF-LIFE ,Activities of Daily Living ,Immunology and Allergy ,Pharmacology (medical) ,Kidney transplantation ,education.field_of_study ,STAGE RENAL-DISEASE ,Prognosis ,Social Participation ,practice ,TRIALS ,quality of life (QOL) ,RELIABILITY ,Patient-reported outcome ,SOCIAL-PARTICIPATION ,HEALTH ,Life Sciences & Biomedicine ,social sciences ,medicine.medical_specialty ,Population ,nephrology ,QUESTIONNAIRE ,kidney transplantation ,03 medical and health sciences ,Quality of life (healthcare) ,medicine ,Humans ,Patient Reported Outcome Measures ,VALIDITY ,education ,Dialysis ,Transplantation ,Science & Technology ,business.industry ,DISABILITY ,medicine.disease ,health services and outcomes research ,Kidney Transplantation ,clinical research ,Physical therapy ,Quality of Life ,Surgery ,business ,Kidney disease - Abstract
For many patients with end-stage kidney disease, transplantation improves survival and quality of life compared with dialysis. However, complications and side effects in kidney transplant recipients can limit their ability to participate in activities of daily living including work, study, and recreational activities. The aim of this study was to identify the characteristics, content, and psychometric properties of the outcome measures used to assess life participation in kidney transplant recipients. We searched MEDLINE, Embase, PsycINFO, and CINAHL from inception to July 2018 for all studies that reported life participation in kidney transplant recipients. Two authors identified instruments measuring life participation and reviewed for characteristics. In total, 230 studies were included: 19 (8%) randomized trials, 17 (7%) nonrandomized trials, and 194 (85%) observational studies. Across these studies, we identified 29 different measures that were used to assess life participation. Twelve (41%) measures specifically assessed aspects of life participation (eg, disability assessment, daily activities of living), while 17 (59%) assessed other constructs (eg, quality of life) that included questions on life participation. Validation data to support the use of these measures in kidney transplant recipients were available for only 7 measures. A wide range of measures have been used to assess life participation in kidney transplant recipients, but validation data supporting the use of these measures in this population are sparse. A content relevant and validated measure to improve the consistency and accuracy of measuring life participation in research may inform strategies for transplant recipients to be better able to engage in their life activities. ispartof: AMERICAN JOURNAL OF TRANSPLANTATION vol:19 issue:8 pages:2306-2317 ispartof: location:United States status: published
- Published
- 2018
48. Is quality of life a suitable measure of patient decision aid effectiveness? Sub-analysis of a Cochrane systematic review
- Author
-
Dawn Stacey, Intissar Souli, Anne Lyddiatt, Phyllis Butow, Claudia Rutherford, Madeleine King, and Orlando Rincones
- Subjects
Study groups ,medicine.medical_specialty ,Health Status ,Decision Making ,Context (language use) ,Aid effectiveness ,law.invention ,Decision Support Techniques ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,Randomized controlled trial ,law ,Medicine ,Humans ,Qualitative Research ,Randomized Controlled Trials as Topic ,Study quality ,business.industry ,030503 health policy & services ,Public Health, Environmental and Occupational Health ,humanities ,030220 oncology & carcinogenesis ,Usual care ,Physical therapy ,Quality of Life ,Treatment decision making ,0305 other medical science ,business ,Systematic Reviews as Topic - Abstract
Patient decision-aids (PtDAs) help patients make informed treatment decisions incorporating their values. Health-related quality of life (HRQOL) is sometimes an outcome of PtDA effectiveness trials, but its suitability for this purpose is unclear. We sought to provide insights into this question by critically appraising how randomized controlled trials (RCTs) evaluating PtDA effectiveness measure and report HRQOL. We conducted a sub-analysis of RCTs included in the 2017 Cochrane review of PtDAs. Trials assessing HRQOL at baseline and post-PtDA, and comparing PtDA with comparison groups were included. Two reviewers independently extracted data and assessed study quality. Analysis was descriptive. Of 105 RCTs, 11 were eligible for inclusion. Patients randomized to PtDAs did not report better HRQOL than those randomized to usual care. While all 11 RCTs adequately described baseline sample characteristics and reported HRQOL results for study groups, few stated a priori HRQOL expectations or hypotheses (36%); made a link between HRQOL and the decision (18%); provided a rationale or justification for HRQOL assessment (18%); provided reason for choice of HRQOL assessment time-points (9%); or adjusted p-values for multiple HRQOL domains and time-points (0%). PtDAs did not conclusively impact HRQOL. If this holds generally, then HRQOL is an uninformative endpoint for PtDA effectiveness trials. When planning trials of PtDAs, investigators considering HRQOL endpoints should consider whether and why their PtDA is likely to affect HRQOL in their context, and if so, which specific aspect(s) of HRQOL and at which time-point(s), and ensure HRQOL is assessed accordingly.
- Published
- 2018
49. The Leeds Assessment of Neuropathic Symptoms and Signs Scale (LANSS) is not an adequate outcome measure of pressure ulcer-related neuropathic pain
- Author
-
Julia Brown, Jane Nixon, Mike Horton, Claudia Rutherford, and Michelle Briggs
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Psychometrics ,Cohort Studies ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Cronbach's alpha ,Pain assessment ,Outcome Assessment, Health Care ,Chi-square test ,medicine ,Humans ,030212 general & internal medicine ,Aged ,Pain Measurement ,Aged, 80 and over ,Pressure Ulcer ,Rasch model ,030504 nursing ,Reproducibility of Results ,Construct validity ,Middle Aged ,Differential item functioning ,Confirmatory factor analysis ,Anesthesiology and Pain Medicine ,Neuropathic pain ,Physical therapy ,Neuralgia ,Female ,Symptom Assessment ,0305 other medical science ,Psychology - Abstract
Few pain assessment scales have been used in pressure ulcer (PU) research and none developed or validated for people with PUs. We examined the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) scale to determine its utility as an outcome measure for people with pressure area-related pain.Leeds Assessment of Neuropathic Symptoms and Signs data from 728 participants underwent psychometric analyses: traditional tests for data quality, scaling assumptions, reliability and validity and a Rasch analysis including tests of fit, spread and targeting of item locations, response dependency, person separation index (reliability) and differential item functioning.Our findings offer support for a unidimensional scale; confirmatory factor analysis indicated a non-significant chi-square test of model fit [(df = 14) 23.48, p = 0.053]. However, some misfit was identified at the overall scale and individual item levels, and internal construct validity of the LANSS as an outcome measure for neuropathic pain in people with pressure area-related pain was not supported; low to moderate item-total correlations [Chi Square (df = 28) 55.546, p = 0.002] and inter-item correlations (mean 0.117 and range from 0.063 to 0.415); and low Cronbach's alpha (0.549) and Person Separation Index (0.334).Requirements for reliable and valid measurement do not support the use of the LANSS as an outcome measure in people with PUs at the individual level or as a generalized measurement scale of neuropathic pain across ulcer severity groups. Expanding the number of items to aid differentiation between neuropathic pain levels and improving scale reliability is recommended. WHAT DOES THIS STUDY ADD?: The Leeds Assessment of Neuropathic Symptoms and Signs scale (LANSS) is not suitable as an outcome measure of pressure ulcer-related neuropathic pain as it did not meet requirements for reliable and valid measurement in this population.
- Published
- 2016
50. The Impact of Cancer on Psychological and Social Outcomes
- Author
-
Madeleine King, Daniel S.J. Costa, Rebecca Mercieca-Bebber, Claudia Rutherford, and Liam Gabb
- Subjects
Psychological intervention ,Cancer ,Cognition ,medicine.disease ,03 medical and health sciences ,Social support ,0302 clinical medicine ,Consistency (negotiation) ,Arts and Humanities (miscellaneous) ,030220 oncology & carcinogenesis ,Survivorship curve ,medicine ,Anxiety ,030212 general & internal medicine ,medicine.symptom ,Psychology ,Psychosocial ,General Psychology ,Clinical psychology - Abstract
Cancer is now the biggest cause of mortality worldwide. Although the debilitating physical symptoms of cancer have long been known, the psychological and social impacts of cancer have become the subject of examination only relatively recently. The psychological outcomes that have been examined are primarily negative emotional variables, e.g., anxiety, but emerging research has focused on positive emotional variables, e.g., post-traumatic growth, or cognitive outcomes. In this article, we provide a synthesis of reviews that have addressed the psychosocial impact of cancer. The framework for this synthesis is provided by a conceptualisation in which the presence of cancer impacts on psychosocial outcomes either directly or via mediating variables, including physical symptoms and treatment, and that this effect may be moderated by several variables, some characteristic of the person with cancer (demographic or personality-related variables) and some characteristic of their environment (social support and medical variables). We also briefly examine the impact of cancer on the broader family unit following cancer diagnosis, treatment, survivorship and bereavement. We conclude that the heterogeneity of the cancer experience highlights the need for theoretically driven research and consistency in measurement approaches to determine mechanisms by which cancer exerts influence on psychosocial outcomes. This would allow development and delivery of targeted psychological interventions and a clearer delineation of the roles of the various parties, including clinical psychologists, family members and policymakers.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.